智通财经12月21日讯（编辑 笠晨）近年来A股上市公司分红意愿显著提升，市场分红生态持续优化，呈 现出分红总额、参与分红公司数量占比以及年内多次分红公司数量逐年递增的趋势。choice数据统计， 截至发稿，以股权登记日计算，今年以来A股上市公司现金分红总额达到2.61万亿元，已超过2024年全 年，创出历史新高。 Wind数据显示，今年以来，A股上市公司迈瑞医疗、三七互娱、御银股份和玲珑轮胎分红次数均为三 次。山东路桥、雅戈尔、深圳华强、奕帆传动、陕国投A、鱼跃医疗、行动教育、南山铝业、隆扬电 子、艾融软件、分众传媒、药明康德、百龙创园、吉比特、华宝股份、新坐标、龙佰集团、远翔新材、 华明装备、卓创资讯、九强生物、金帝股份、开普检测、西部证券、海希通讯、开能健康、金能科技、 金岭矿业、国光股份和吉电股份分红次数均为两次。具体情况如下图： | 证券简称 | 分红总额 | 分红次数 | Wind行业 | | --- | --- | --- | --- | | | (亿元) | | | | 三七互娱 | 13. 86 | 3 | 传媒 | | 玲珑轮胎 | 3.59 | 3 | 汽车与零配件 | | 迈瑞医疗 | ...

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Insights - The overall market is experiencing a pullback driven by technology giants, with the Hang Seng Index down by 1.1% and the Hang Seng Composite Index down by 1.2% [1] - Valuation levels for most industries are declining, with the Hang Seng Index's forward P/E ratio decreasing by 1.7% to 11.6x [2] - Earnings expectations have been adjusted upwards overall, with the Hang Seng Index's EPS increasing by 0.3% compared to the previous week [3] Summary by Sections Market Performance - The Hang Seng Index decreased by 1.1%, while the Hang Seng Composite Index fell by 1.2%. Mid-cap stocks outperformed small-cap and large-cap stocks [1] - Among major concept indices, the Hang Seng Consumer Index rose by 0.3%, while the Hang Seng Internet Index dropped by 2.9% [1] Valuation Levels - The valuation of the Hang Seng Index decreased by 1.7% to 11.6x, and the Hang Seng Composite Index's valuation fell by 2.4% to 11.4x [2] - The most significant valuation increase was in the basic chemicals sector (+11.6%), while the real estate sector saw the largest decline (-19.0%) [2] Earnings Expectations - The EPS for the Hang Seng Index increased by 0.3%, and the Hang Seng Composite Index's EPS rose by 1.2% compared to the previous week [3] - The real estate sector saw a substantial EPS upward revision of 20.5%, while the basic chemicals sector experienced a downward revision of 10.2% [3]

从美的集团方面获悉，美的医疗近日正式发布具备国产自主知识产权的"医学影像多模态智能诊断大模 型"。该模型目前可一次性自动检测出包括肺结核、肺炎、气胸、骨折等在内的常见胸部疾病，并生成 诊断报告。美的医疗旗下万里云研发团队还创新推出了可同时满足设备端与云端灵活部署的"双量级"模 型，增强了临床应用的适应性。当前模型主要应用于胸部DR诊断，并计划于2026年迭代拓展至骨科DR 领域，未来将逐步延伸至CT、MRI等多模态影像场景。 ...

企业负责人把文化做好，战略、投资决策、选人用人、风险防范才能做好。 文｜《中国企业家》记者 马吉英 见习记者 苗诗雨 编辑｜马吉英 见习编辑｜张昊 图片来源｜中企图库 12月6～7日，由《中国企业家》杂志社主办的2025（第二十三届）影响力企业家年会（原中国企业领袖年会）在北京召开。在7日的主旨演讲环节，中国 建材股份有限公司执行董事、副总裁王兵针对《文化和善治》进行了主题演讲。 以下为核心观点： 1.文化不仅是领导说的、墙上贴的，还要看是否言行合一和上行下效，它应该是领导和员工的真实行事方式。 4.新上任的董事长、总经理都要想一想，卸任以后，你的任期是否会被历史认为是企业的"垃圾时间"，甚至你是否是企业的"罪人"。如果经常问自己这两 句话，你就会做出正确的决策。 以下为现场演讲实录（有删减）： 刚才江南春作为现任的上市公司董事长讲得很好，我是作为卸任的上市公司董事长交流一下复盘和思考。 文化是什么？是使命、愿景、价值观，是公司治理、行为准则、企业文化等的总和。文化不仅是领导说的、墙上贴的，还要看是否言行合一和上行下效， 它应该是领导和员工的真实行事方式。 文化是企业的软实力和竞争力。没有好的文化，公司治理也 ...

Economic Outlook - The US economy is expected to gradually move towards expansion in 2026, with economic growth potentially higher than in 2025, characterized by a front-loaded low and a back-loaded high throughout the year [5][15]. - The first quarter of 2026 may represent a relative low point due to the prolonged government shutdown in October 2025, but subsequent recovery is anticipated driven by fiscal and monetary policy support [15][37]. - Consumer spending is projected to steadily recover, supported by the gradual realization of benefits from the "Big Beautiful Act" (OBBBA), which will reduce tax burdens and increase disposable income [15][20]. Market Performance - The US stock market is expected to see further gains in 2026, primarily driven by earnings growth, with an overall EPS increase of over 12% anticipated [5][43]. - The technology sector is expected to continue its dominance in the first half of 2026, while a shift towards cyclical sectors is anticipated in the latter half as economic recovery progresses [49][50]. Sector Analysis - Small-cap stocks are expected to show greater elasticity in 2026, supported by lower borrowing costs and pent-up demand as the economy enters the early stages of recovery [5][49]. - The technology sector is projected to maintain its leading position in the first half of the year, with significant contributions from earnings, while the second half may present risks due to potential stagnation in capital expenditures [49][50]. - Cyclical sectors such as industrials, real estate, consumer discretionary, and financials are expected to benefit from the economic recovery, particularly as real estate begins to thaw and new home sales show signs of improvement [5][49][57].

Core Viewpoint - The stock of Hezhong China has achieved 16 consecutive trading limits within 27 days, indicating strong market interest and performance in the context of the active pharmaceutical retail sector [1] Company Summary - Hezhong China's main business includes in vitro diagnostic products and is advancing its digital transformation in healthcare [1] - The "Maitaiwei" surgical medical education and research digital platform has gained market attention due to its implementation progress [1] Market Activity - The stock reached a trading limit today at 9:30 AM with a transaction volume of 509 million yuan and a turnover rate of 4.39% [1] - The overall activity in the pharmaceutical retail sector has led to increased speculation and investment in related concepts, positively impacting stock performance [1]

Core Viewpoint - The stock of HeFu China (603122) opened down by 6.1% at a price of 24 CNY per share following the announcement of a planned share reduction by its controlling shareholder [1] Group 1: Share Reduction Announcement - HeFu China announced that its controlling shareholder, HeFu (Hong Kong) Holdings Limited, plans to reduce its shareholding by a total of up to 7.9611 million shares, which represents no more than 2% of the company's total share capital [1] - The reason for the share reduction is to raise operational funds, including financing for the development of a magnetic resonance imaging (MRI) navigation radiation therapy system project [1]

Core Viewpoint - The automotive and parts sector in A-shares has seen significant net buying in financing, ranking among the top five, while sectors such as steel II, pharmaceuticals, telecommunications services, medical devices, and non-bank financials have ranked among the bottom five in net buying [24]. Market Overview - As of November 28, 2025, the financing net buying amounts for various sectors have shown a clear disparity, with 23 out of 35 Wind secondary industry sectors experiencing net buying [24][25]. - The major indices in A-shares have all risen, with the Wind All A Index increasing by 2.90%, the Shanghai Composite Index by 1.40%, the Shenzhen Component Index by 3.56%, the ChiNext Index by 4.54%, the North 50 Index by 0.75%, and the Sci-Tech 50 Index by 3.21% [23]. Financing Net Buying Rankings - The top five sectors for net buying in the past week include: - Industrial Trade and Comprehensive: 94.90 billion - Semiconductor: 33.84 billion - Automotive and Parts: 7.81 billion - Hardware Equipment: 6.82 billion - Transportation: 6.57 billion [31] - The bottom five sectors for net buying in the past week include: - Medical Devices and Services: -1.31 billion - Steel II: -1.99 billion - Pharmaceuticals: -3.89 billion - Telecommunications Services: -4.90 billion - Non-Bank Financials: -24.50 billion [32]. Financing Balance Rankings - The top five sectors by financing balance are: - Hardware Equipment: 3,446.36 billion - Non-Bank Financials: 1,827.97 billion - Semiconductors: 1,800.99 billion - Electrical Equipment: 1,791.24 billion - Software Services: 1,500.74 billion [33].

Core Viewpoint - The stock of HeFu China reached a limit-up on December 2, closing at 25.56 yuan per share, with a total market capitalization of 10.174 billion yuan, driven by policy support and business developments [1] Group 1: Stock Performance - HeFu China closed at 25.56 yuan per share on December 2, with a trading volume of 2.478 billion yuan and a market cap of 10.174 billion yuan [1] - The stock has experienced 14 limit-ups over the past 23 trading days [1] Group 2: Factors Influencing Stock Movement - Policy factors include the release of the fifth batch of measures by the Fujian government to promote cross-strait integration, addressing the needs of Taiwanese individuals and enterprises [1] - The company's business is related to the sales and supply chain management of in vitro diagnostic products, covering over 3,700 items from more than 1,000 manufacturers, providing customized cost-reduction solutions for medical institutions [1] - HeFu China has developed a digital management software called "ZhiBeiTa" for hospital department operation management, facilitating cross-strait medical resource exchange [1] Group 3: Financial Performance - For the period from January to September 2025, HeFu China reported operating revenue of 549 million yuan, a year-on-year decrease of 22.80% [1] - The net profit attributable to the parent company was -12.3862 million yuan, representing a year-on-year decrease of 146.65% [1]

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased by 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [7][9] - For the nine months ended September 30, 2025, revenue increased by approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9][12] - Gross profit for Q3 2025 increased by approximately $1.6 million to $3.9 million, with gross margin slightly decreasing to 58% from 60% in Q3 2024 [11][12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada, and $1.3 million from new treatment centers [8][9] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new business model [9][10] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at the Sleep Center of Nevada, indicating substantial growth potential [24] - Over 210,000 OSA patients have been tested and seen by SCN providers since 2019, with many legacy patients potentially seeking alternatives to CPAP [24] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and forming alliances is aimed at increasing market penetration and financial returns [19][20] - The establishment of Sleep and Airway Medicine Centers (SAMHSA Centers) is part of the strategy to educate and evaluate patients for treatment options [22][30] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating a significant inflection point in the company's ability to monetize its technology for treating sleep-related disorders [16][19] - The company expects revenue growth to outpace expenses as new teams are deployed and operational efficiencies are realized [23][33] Other Important Information - The company has secured $14.2 million in net cash from financing activities, which will support its growth initiatives [13] - General and administrative expenses increased by approximately $5.7 million, primarily due to costs associated with the Sleep Center of Nevada operations [12] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new dental providers and nurse practitioners are added to the teams [35] Question: What is the expected ramp-up time for revenue generation? - A ramp-up period of approximately three to six months is anticipated to reach optimized revenue levels [36] Question: What are the expected contribution margins for SAMHSA operations? - Steady-state operations are expected to yield contribution margins of 50%-60% [38] Question: What is the goal for cash flow break-even? - The goal is to achieve cash flow break-even, with ongoing efforts to manage growth and operational expenses [39] Question: How should investors view the company now and in six months? - Management believes the company has finally found a monetization model that aligns with its technological advantages, indicating strong future growth potential [41][42]